{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T21:09:58Z","timestamp":1791839398473,"version":"4.3.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T00:00:00Z","timestamp":1775433600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":52,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303526"],"award-info":[{"award-number":["82303526"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82403073"],"award-info":[{"award-number":["82403073"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Natural Science Foundation of the Hunan Province of China","award":["2024JJ6590"],"award-info":[{"award-number":["2024JJ6590"]}]},{"name":"the Natural Science Foundation of the Hunan Province of China","award":["2022JJ40704"],"award-info":[{"award-number":["2022JJ40704"]}]},{"name":"the Natural Science Foundation of the Hunan Province of China","award":["2023JJ40842"],"award-info":[{"award-number":["2023JJ40842"]}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M743946"],"award-info":[{"award-number":["2023M743946"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002858","name":"the China Postdoctoral Science Foundation","doi-asserted-by":"crossref","award":["2023M733955"],"award-info":[{"award-number":["2023M733955"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Open Funds of State Key Laboratory of Oncology in South China","award":["HN2024-04"],"award-info":[{"award-number":["HN2024-04"]}]},{"name":"the Open Funds of State Key Laboratory of Oncology in South China","award":["NH2024-07"],"award-info":[{"award-number":["NH2024-07"]}]},{"name":"the Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["QH20230256"],"award-info":[{"award-number":["QH20230256"]}]},{"name":"the Scientific Research Launch Project for new employees of the Second Xiangya Hospital of Central South University","award":["QH20230268"],"award-info":[{"award-number":["QH20230268"]}]},{"name":"the Education and Teaching Reform Research Project of Central South University","award":["2022JY197"],"award-info":[{"award-number":["2022JY197"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-47187-1","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:33:35Z","timestamp":1775500415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prognostic significance and immune correlation of STING expression and promoter methylation in renal cell carcinoma"],"prefix":"10.1038","volume":"16","author":[{"given":"Shirong","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao\u2019ran","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishu","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"issue":"1","key":"47187_CR1","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72 (1), 7\u201333 (2022).","journal-title":"CA Cancer J. Clin."},{"issue":"8","key":"47187_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1016\/j.ccell.2023.07.006","volume":"41","author":"EP Henske","year":"2023","unstructured":"Henske, E. P., Cheng, L., Hakimi, A. A., Choueiri, T. K. & Braun, D. A. Chromophobe renal cell carcinoma. Cancer Cell. 41 (8), 1383\u20131388 (2023).","journal-title":"Cancer Cell."},{"issue":"8","key":"47187_CR3","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/jamaoncol.2023.1822","volume":"9","author":"J Saal","year":"2023","unstructured":"Saal, J. et al. Integrating on-treatment modified glasgow prognostic score and imaging to predict response and outcomes in metastatic renal cell carcinoma. JAMA Oncol. 9 (8), 1048\u20131055 (2023).","journal-title":"JAMA Oncol."},{"issue":"8","key":"47187_CR4","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1001\/jamaoncol.2023.1764","volume":"9","author":"G Gebrael","year":"2023","unstructured":"Gebrael, G., Fortuna, G. G. & Agarwal, N. Developing an ideal risk stratification model for metastatic renal cell carcinoma. JAMA Oncol. 9 (8), 1033\u20131035 (2023).","journal-title":"JAMA Oncol."},{"issue":"7","key":"47187_CR5","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41581-024-00855-9","volume":"20","author":"EF Carney","year":"2024","unstructured":"Carney, E. F. Mutational signatures of ccRCC vary between geographical regions. Nat. Rev. Nephrol. 20 (7), 429 (2024).","journal-title":"Nat. Rev. Nephrol."},{"issue":"2","key":"47187_CR6","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1056\/NEJMc2406031","volume":"391","author":"NH Chakiryan","year":"2024","unstructured":"Chakiryan, N. H. & Strother, M. C. Adjuvant pembrolizumab in renal-cell carcinoma. N Engl. J. Med. 391 (2), 185\u2013186 (2024).","journal-title":"N Engl. J. Med."},{"issue":"10446","key":"47187_CR7","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1016\/S0140-6736(24)01178-4","volume":"403","author":"C Wirbel","year":"2024","unstructured":"Wirbel, C. et al. Multi-system involvement-including purpura fulminans-as an adverse effects of immune checkpoint inhibitor therapy for clear cell renal cell carcinoma. Lancet 403 (10446), 2818\u20132819 (2024).","journal-title":"Lancet"},{"issue":"3","key":"47187_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1158\/2159-8290.CD-23-0680","volume":"14","author":"TK Choueiri","year":"2024","unstructured":"Choueiri, T. K. et al. Integrative analyses of tumor and peripheral biomarkers in the treatment of advanced renal cell carcinoma. Cancer Discov. 14 (3), 406\u2013423 (2024).","journal-title":"Cancer Discov"},{"issue":"5","key":"47187_CR9","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/j.ccell.2024.03.002","volume":"42","author":"RM Saliby","year":"2024","unstructured":"Saliby, R. M. et al. Impact of renal cell carcinoma molecular subtypes on immunotherapy and targeted therapy outcomes. Cancer Cell. 42 (5), 732\u2013735 (2024).","journal-title":"Cancer Cell."},{"issue":"5","key":"47187_CR10","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1016\/j.ccell.2024.04.003","volume":"42","author":"C Hage Chehade","year":"2024","unstructured":"Hage Chehade, C. & Agarwal, N. Molecular subtypes as potential biomarkers in renal cell carcinoma. Cancer Cell. 42 (5), 736\u2013738 (2024).","journal-title":"Cancer Cell."},{"issue":"7","key":"47187_CR11","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41581-023-00700-5","volume":"19","author":"MM Wolf","year":"2023","unstructured":"Wolf, M. M., Rathmell, W. K. & de Cubas, A. A. Immunogenicity in renal cell carcinoma: shifting focus to alternative sources of tumour-specific antigens. Nat. Rev. Nephrol. 19 (7), 440\u2013450 (2023).","journal-title":"Nat. Rev. Nephrol."},{"issue":"7","key":"47187_CR12","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41590-024-01872-3","volume":"25","author":"KRB Lanng","year":"2024","unstructured":"Lanng, K. R. B., Lauridsen, E. L. & Jakobsen, M. R. The balance of STING signaling orchestrates immunity in cancer. Nat. Immunol. 25 (7), 1144\u20131157 (2024).","journal-title":"Nat. Immunol."},{"issue":"10","key":"47187_CR13","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.immuni.2023.07.018","volume":"56","author":"LL Cao","year":"2023","unstructured":"Cao, L. L. & Kagan, J. C. Targeting innate immune pathways for cancer immunotherapy. Immunity 56 (10), 2206\u20132217 (2023).","journal-title":"Immunity"},{"issue":"13","key":"47187_CR14","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","volume":"187","author":"MB Maxwell","year":"2024","unstructured":"Maxwell, M. B. et al. ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity. Cell 187 (13), 3390\u20133408 (2024). e3319.","journal-title":"Cell"},{"issue":"7931","key":"47187_CR15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/s41586-022-05254-3","volume":"610","author":"S Li","year":"2022","unstructured":"Li, S. et al. STING-induced regulatory B cells compromise NK function in cancer immunity. Nature 610 (7931), 373\u2013380 (2022).","journal-title":"Nature"},{"issue":"7976","key":"47187_CR16","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41586-023-06464-z","volume":"620","author":"J Li","year":"2023","unstructured":"Li, J. et al. Non-cell-autonomous cancer progression from chromosomal instability. Nature 620 (7976), 1080\u20131088 (2023).","journal-title":"Nature"},{"issue":"4","key":"47187_CR17","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.cell.2024.01.008","volume":"187","author":"G Leuzzi","year":"2024","unstructured":"Leuzzi, G. et al. SMARCAL1 is a dual regulator of innate immune signaling and PD-L1 expression that promotes tumor immune evasion. Cell 187 (4), 861\u2013881e832 (2024).","journal-title":"Cell"},{"key":"47187_CR18","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1146\/annurev-biochem-040320-101629","volume":"91","author":"C Ritchie","year":"2022","unstructured":"Ritchie, C., Carozza, J. A. & Li, L. Biochemistry, cell biology, and pathophysiology of the innate immune cGAS-cGAMP-STING pathway. Annu. Rev. Biochem. 91, 599\u2013628 (2022).","journal-title":"Annu. Rev. Biochem."},{"key":"47187_CR19","doi-asserted-by":"crossref","unstructured":"Shim, H. S. et al. TERT activation targets DNA methylation and multiple aging hallmarks. Cell (2024).","DOI":"10.1016\/j.cell.2024.05.048"},{"key":"47187_CR20","doi-asserted-by":"crossref","unstructured":"Schreiberhuber, L. et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat. Med. (2024).","DOI":"10.1038\/s41591-024-03014-6"},{"issue":"7","key":"47187_CR21","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1038\/s41591-024-02995-8","volume":"30","author":"DT Hoang","year":"2024","unstructured":"Hoang, D. T. et al. Prediction of DNA methylation-based tumor types from histopathology in central nervous system tumors with deep learning. Nat. Med. 30 (7), 1952\u20131961 (2024).","journal-title":"Nat. Med."},{"issue":"6705","key":"47187_CR22","doi-asserted-by":"publisher","first-page":"eadl6173","DOI":"10.1126\/science.adl6173","volume":"385","author":"MJ Wu","year":"2024","unstructured":"Wu, M. J. et al. Mutant IDH1 inhibition induces dsDNA sensing to activate tumor immunity. Science 385 (6705), eadl6173 (2024).","journal-title":"Science"},{"issue":"12","key":"47187_CR23","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1001\/jamaoncol.2023.4736","volume":"9","author":"B Zhao","year":"2023","unstructured":"Zhao, B., Qi, H. & Ma, W. MGMT promoter methylation and chemotherapy outcomes in low-grade and anaplastic gliomas. JAMA Oncol. 9 (12), 1734\u20131735 (2023).","journal-title":"JAMA Oncol."},{"issue":"12","key":"47187_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.2217\/imt-2020-0037","volume":"12","author":"L Vos","year":"2020","unstructured":"Vos, L. et al. PD-1, CTLA4, PD-L1 and PD-L2 DNA methylation in papillary thyroid carcinoma. Immunotherapy 12 (12), 903\u2013920 (2020).","journal-title":"Immunotherapy"},{"key":"47187_CR25","doi-asserted-by":"crossref","unstructured":"Sukowati, C. et al. PD-L1 Downregulation and DNA methylation inhibition for molecular therapy against cancer stem cells in hepatocellular carcinoma. Int J. Mol. Sci 24 (17). (2023).","DOI":"10.3390\/ijms241713357"},{"issue":"1","key":"47187_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13148-023-01525-6","volume":"15","author":"F Hoffmann","year":"2023","unstructured":"Hoffmann, F. et al. CTLA4 DNA methylation is associated with CTLA-4 expression and predicts response to immunotherapy in head and neck squamous cell carcinoma. Clin. Epigenetics. 15 (1), 112 (2023).","journal-title":"Clin. Epigenetics"},{"issue":"22","key":"47187_CR27","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1161\/CIRCULATIONAHA.123.065344","volume":"148","author":"M Yalcinkaya","year":"2023","unstructured":"Yalcinkaya, M. et al. BRCC3-mediated NLRP3 deubiquitylation promotes inflammasome activation and atherosclerosis in Tet2 clonal hematopoiesis. Circulation 148 (22), 1764\u20131777 (2023).","journal-title":"Circulation"},{"issue":"1","key":"47187_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12943-020-01170-0","volume":"19","author":"B Zhang","year":"2020","unstructured":"Zhang, B. et al. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol. Cancer. 19 (1), 53 (2020).","journal-title":"Mol. Cancer"},{"key":"47187_CR29","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-2105-14-7","volume":"14","author":"S Hanzelmann","year":"2013","unstructured":"Hanzelmann, S., Castelo, R. & Guinney, J. GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform. 14, 7 (2013).","journal-title":"BMC Bioinform."},{"issue":"7693","key":"47187_CR30","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan, S. et al. TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554 (7693), 544\u2013548 (2018).","journal-title":"Nature"},{"issue":"1","key":"47187_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1186\/s13059-016-1092-z","volume":"17","author":"Y Senbabaoglu","year":"2016","unstructured":"Senbabaoglu, Y. et al. Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. Genome Biol. 17 (1), 231 (2016).","journal-title":"Genome Biol."},{"issue":"10031","key":"47187_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 (10031), 1909\u20131920 (2016).","journal-title":"Lancet"},{"issue":"2","key":"47187_CR33","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccell.2024.01.001","volume":"42","author":"S Heeke","year":"2024","unstructured":"Heeke, S. et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 42 (2), 225\u2013237 (2024). e225.","journal-title":"Cancer Cell."},{"issue":"9","key":"47187_CR34","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1016\/j.ccell.2023.07.013","volume":"41","author":"WW Liang","year":"2023","unstructured":"Liang, W. W. et al. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin. Cancer Cell. 41 (9), 1567\u20131585 (2023). e1567.","journal-title":"Cancer Cell."},{"issue":"10","key":"47187_CR35","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1158\/2159-8290.CD-21-1252","volume":"13","author":"AK Mattox","year":"2023","unstructured":"Mattox, A. K. et al. The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer. Cancer Discov. 13 (10), 2166\u20132179 (2023).","journal-title":"Cancer Discov"},{"issue":"8","key":"47187_CR36","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1038\/s41588-023-01448-1","volume":"55","author":"Genome-wide mutation profiles","year":"2023","unstructured":"Genome-wide mutation profiles. from cell-free DNA for early cancer detection. Nat. Genet. 55 (8), 1261\u20131262 (2023).","journal-title":"Nat. Genet."},{"key":"47187_CR37","doi-asserted-by":"crossref","unstructured":"Zhao, S. G. et al. Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer. Nat.  Genet. (2024).","DOI":"10.1038\/s41588-024-01826-3"},{"issue":"8","key":"47187_CR38","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/s41588-023-01437-4","volume":"55","author":"C Esnault","year":"2023","unstructured":"Esnault, C. et al. G4access identifies G-quadruplexes and their associations with open chromatin and imprinting control regions. Nat. Genet. 55 (8), 1359\u20131369 (2023).","journal-title":"Nat. Genet."},{"issue":"6","key":"47187_CR39","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1038\/s41591-023-02369-6","volume":"29","author":"J Lv","year":"2023","unstructured":"Lv, J. et al. The tumor immune microenvironment of nasopharyngeal carcinoma after gemcitabine plus cisplatin treatment. Nat. Med. 29 (6), 1424\u20131436 (2023).","journal-title":"Nat. Med."},{"key":"47187_CR40","doi-asserted-by":"crossref","unstructured":"Kim, H. et al. PRMT5 control of cGAS\/STING and NLRC5 pathways defines melanoma response to antitumor immunity. Sci. Transl. Med. 12(551). (2020).","DOI":"10.1126\/scitranslmed.aaz5683"},{"issue":"11","key":"47187_CR41","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/s41573-020-0077-5","volume":"19","author":"SJ Hogg","year":"2020","unstructured":"Hogg, S. J., Beavis, P. A., Dawson, M. A. & Johnstone, R. W. Targeting the epigenetic regulation of antitumour immunity. Nat. Rev. Drug Discov. 19 (11), 776\u2013800 (2020).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"1","key":"47187_CR42","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1146\/annurev-immunol-080223-044610","volume":"42","author":"IF Lopez-Moyado","year":"2024","unstructured":"Lopez-Moyado, I. F., Ko, M., Hogan, P. G. & Rao, A. TET enzymes in the immune system: From DNA demethylation to immunotherapy, inflammation, and cancer. Annu. Rev. Immunol. 42 (1), 455\u2013488 (2024).","journal-title":"Annu. Rev. Immunol."},{"issue":"1","key":"47187_CR43","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s12943-021-01464-x","volume":"20","author":"E Dai","year":"2021","unstructured":"Dai, E. et al. Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. Mol. Cancer. 20 (1), 171 (2021).","journal-title":"Mol. Cancer"},{"issue":"2","key":"47187_CR44","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1093\/neuonc\/noaa247","volume":"23","author":"J Dejaegher","year":"2021","unstructured":"Dejaegher, J. et al. DNA methylation based glioblastoma subclassification is related to tumoral T-cell infiltration and patient survival. Neuro Oncol. 23 (2), 240\u2013250 (2021).","journal-title":"Neuro Oncol."},{"issue":"4","key":"47187_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41571-020-00455-z","volume":"18","author":"DA Braun","year":"2021","unstructured":"Braun, D. A. et al. Beyond conventional immune-checkpoint inhibition - novel immunotherapies for renal cell carcinoma. Nat. Rev. Clin. Oncol. 18 (4), 199\u2013214 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"47187_CR46","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41568-024-00674-x","volume":"24","author":"P Meier","year":"2024","unstructured":"Meier, P., Legrand, A. J., Adam, D. & Silke, J. Immunogenic cell death in cancer: targeting necroptosis to induce antitumour immunity. Nat. Rev. Cancer. 24 (5), 299\u2013315 (2024).","journal-title":"Nat. Rev. Cancer"},{"issue":"12","key":"47187_CR47","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1038\/s41573-023-00809-z","volume":"22","author":"CA Klebanoff","year":"2023","unstructured":"Klebanoff, C. A., Chandran, S. S., Baker, B. M., Quezada, S. A. & Ribas, A. T cell receptor therapeutics: immunological targeting of the intracellular cancer proteome. Nat. Rev. Drug Discov. 22 (12), 996\u20131017 (2023).","journal-title":"Nat. Rev. Drug Discov"},{"issue":"1","key":"47187_CR48","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","volume":"187","author":"Q Liu","year":"2024","unstructured":"Liu, Q. et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell 187 (1), 184\u2013203e128 (2024).","journal-title":"Cell"},{"issue":"23","key":"47187_CR49","doi-asserted-by":"publisher","first-page":"e2310189","DOI":"10.1002\/adma.202310189","volume":"36","author":"H Yang","year":"2024","unstructured":"Yang, H., Yang, S., Guo, Q., Sheng, J. & Mao, Z. ATP-responsive manganese-based bacterial materials synergistically activate the cGAS-STING pathway for tumor immunotherapy. Adv. Mater. 36 (23), e2310189 (2024).","journal-title":"Adv. Mater."},{"issue":"7918","key":"47187_CR50","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/s41586-022-04847-2","volume":"607","author":"C Hong","year":"2022","unstructured":"Hong, C. et al. cGAS-STING drives the IL-6-dependent survival of chromosomally instable cancers. Nature 607 (7918), 366\u2013373 (2022).","journal-title":"Nature"},{"key":"47187_CR51","doi-asserted-by":"crossref","unstructured":"Li, W. et al. cGAS-STING-mediated DNA sensing maintains CD8(+) T cell stemness and promotes antitumor T cell therapy. Sci Transl Med 12(549). (2020).","DOI":"10.1126\/scitranslmed.aay9013"},{"issue":"4","key":"47187_CR52","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1038\/s41419-024-06685-8","volume":"15","author":"X Li","year":"2024","unstructured":"Li, X. et al. Arsenic trioxide augments immunogenic cell death and induces cGAS-STING-IFN pathway activation in hepatocellular carcinoma. Cell. Death Dis. 15 (4), 300 (2024).","journal-title":"Cell. Death Dis."},{"issue":"1","key":"47187_CR53","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12916-024-03375-2","volume":"22","author":"M Li","year":"2024","unstructured":"Li, M. et al. PREX2 contributes to radiation resistance by inhibiting radiotherapy-induced tumor immunogenicity via cGAS\/STING\/IFNs pathway in colorectal cancer. BMC Med. 22 (1), 154 (2024).","journal-title":"BMC Med."},{"issue":"21","key":"47187_CR54","doi-asserted-by":"publisher","first-page":"e2400888","DOI":"10.1002\/advs.202400888","volume":"11","author":"Y Yi","year":"2024","unstructured":"Yi, Y. et al. Mesenchymal stromal cells increase the natural killer resistance of circulating tumor cells via intercellular signaling of cGAS-STING-IFNbeta-HLA. Adv. Sci. (Weinh). 11 (21), e2400888 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"issue":"11","key":"47187_CR55","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41422-020-00395-4","volume":"30","author":"M Lv","year":"2020","unstructured":"Lv, M. et al. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy. Cell. Res. 30 (11), 966\u2013979 (2020).","journal-title":"Cell. Res."},{"issue":"15","key":"47187_CR56","doi-asserted-by":"publisher","first-page":"e2304328","DOI":"10.1002\/adma.202304328","volume":"36","author":"L Yi","year":"2024","unstructured":"Yi, L. et al. A hybrid nanoadjuvant simultaneously depresses PD-L1\/TGF-beta1 and activates cGAS-STING pathway to overcome radio-immunotherapy resistance. Adv. Mater. 36 (15), e2304328 (2024).","journal-title":"Adv. Mater."},{"issue":"21","key":"47187_CR57","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1021\/acs.accounts.3c00394","volume":"56","author":"S Zhou","year":"2023","unstructured":"Zhou, S., Cheng, F., Zhang, Y., Su, T. & Zhu, G. Engineering and delivery of cGAS-STING immunomodulators for the immunotherapy of cancer and autoimmune diseases. Acc. Chem. Res. 56 (21), 2933\u20132943 (2023).","journal-title":"Acc. Chem. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47187-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47187-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T01:02:55Z","timestamp":1779930175000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-47187-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["47187"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-47187-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]},"assertion":[{"value":"10 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Public data was obtained from the TCGA and CPTAC were used. Clinical specimens were obtained from the Tumor Bio-bank of Sun Yat-sen University Cancer Center. The study protocol for the SYSUCC cohort was approved by the Institutional Research Ethics Committee of Sun Yat-sen University Cancer Center (B2020-310-01). All methods were conducted in accordance with relevant guidelines and regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"16542"}}